Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2023 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The transcript is about HEI's earnings call. They discuss utility, bank, renewable projects, etc. Look for any mention of deals, contracts, projects, customers, sites, programs getting bigger over time. Search for phrases like "larger", "bigger", "scale", "size", "increasing", "growing" in context of individual projects or contracts. They talk about CapEx, renewable RFP, IGP plan, etc. But do they say that new projects are individually larger than before? They mention the IGP proposes significant investment, but that's a plan, not necessarily a comparison to past. They talk about smart meters deployment, but that's volume. They mention the bank's deposits stable, not about deal size. No explicit statement about successive engagements being larger. They discuss the RFP process, but not that the size of awards is escalating. They mention the utility's capital plan, but not that individual projects are bigger. The bank's loan growth is low single digit, not about size of individual loans. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.